The U.S. diabetic foot ulcer treatment market size is anticipated to reach USD 2.47 billion by 2030, expanding at a CAGR of 5.25% from 2024 to 2030, according to a new report by Grand View Research, Inc. The major factors contributing to market growth include the increasing occurrence of diabetes nationwide, an aging population, advancements in treatment technology, rising research and development efforts, and shifts in lifestyle patterns. For instance, according to the Population Reference Bureau's projections, the population of Americans aged 65 and older is expected to rise from 58 million in 2022 to 82 million by the year 2050, reflecting a 47% increase.
The prevalence of diabetes in the U.S. plays a significant role in market expansion, as diabetic foot ulcers are a common complication of the disease. For instance, according to the International Diabetes Federation, in 2021 there were about 32.21 million diabetes patients aged 20-79 years in the U.S. which are further expected to increase to 36.28 million by 2045. Furthermore, the advancements in medical technology and treatment modalities contribute to the growth of the market. Innovations such as advanced wound care products, bioengineered tissues, and regenerative medicine techniques offer more effective and efficient solutions for diabetic foot ulcer management.
Furthermore, the increasing awareness among healthcare providers and patients of the importance of early detection and proper treatment of diabetic foot ulcers is driving the market growth. Both healthcare professionals and patients understand the necessity of careful foot care and regular screenings to catch diabetic foot ulcers early. This heightened awareness encourages a proactive approach to managing complications of diabetes, leading to better outcomes for patients and fewer severe ulcers. Additionally, ongoing research and development efforts are essential in advancing treatment options and technologies for managing diabetic foot ulcers. These continued efforts result in innovative solutions, such as new therapies, diagnostic tools, and preventive measures, which expand the options available to healthcare providers.
Presence of major market participants and various initiatives undertaken by them to stay competitive in the market such as product approval, product launch, partnership, merger and acquisition, expansion, etc. are expected to contribute to the overall market growth. For instance, in April 2024, Molnlycke Health Care has announced its plans to acquire P.G.F. Industry Solutions GmbH, an Austrian company known for producing Granudacyn, a line of wound cleansing and moisturizing products.
Request a free sample copy or view report summary: U.S. Diabetic Foot Ulcer Treatment Market Report
Based on treatment, the biologics segment dominated the market by capturing a revenue share of more than 30% in 2023
The therapy devices segment is anticipated to grow at the fastest CAGR during the forecast period
Based on ulcer type, the neuro-ischemic ulcers segment held the largest market share in 2023
The Ischemic ulcers segment is expected to grow at a fastest rate from 2024 to 2030
Based on end-use, hospitals and clinics led the market in 2023
North America dominated the market in 2023
Grand View Research has segmented the U.S. diabetic foot ulcer treatment market based on treatment, ulcer type, and end-use:
U.S. Diabetic Foot Ulcer Treatment Outlook (Revenue, USD Million, 2018 - 2030)
Wound Care Dressings
Alginate Dressings
Hydrofiber Dressings
Foam Dressings
Film Dressing
Hydrocolloid Dressings
Surgical Dressings
Hydrogel Dressings
Biologics
Growth Factors
Skin Grafts
Therapy Devices
Negative Pressure Wound Therapy
Ultrasound Therapy
Antibiotic Medications
Others
U.S. Diabetic Foot Ulcer Treatment Ulcer Type Outlook (Revenue, USD Million, 2018 - 2030)
Ulcers
Ischemic Ulcers
Neuro-ischemic Ulcers
U.S. Diabetic Foot Ulcer Treatment End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Ambulatory surgery centers
Homecare
List Of Key Players In The U.S. Diabetic Foot Ulcer Treatment Market
ConvaTec, Group Plc
3M Health Care
Coloplast Corp.
Smith & Nephew Plc
B Braun Melsungen AG
Medline Industries, LP.
Molnlycke Health Care AB
Medtronic Plc
"The quality of research they have done for us has been excellent..."